XOMA Royalty Corp
XOMAO
Company Profile
Business description
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Contact
2200 Powell Street
Suite 310
EmeryvilleCA94608
USAT: +1 510 204-7200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
Employees
13
Stocks News & Analysis
stocks
10 US stocks with the largest fair value estimate increases during Q4 earnings
Semiconductor companies Sandisk, Teradyne, and Applied Materials saw the largest fair value hikes.
stocks
Berkshire Hathaway earnings: Cash hits record $373 billion on mostly solid results across the firm
We think Berkshire Hathaway stock is fairly valued.
stocks
Magellan Financial Group: A dilutive acquisition of Barrenjoey
Our view of the proposed merger.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,297.20 | 103.50 | -1.10% |
| CAC 40 | 8,103.84 | 290.48 | -3.46% |
| DAX 40 | 23,790.65 | 847.35 | -3.44% |
| Dow JONES (US) | 48,232.25 | 672.53 | -1.38% |
| FTSE 100 | 10,484.13 | 295.98 | -2.75% |
| HKSE | 25,768.08 | 291.77 | -1.12% |
| NASDAQ | 22,416.20 | 332.66 | -1.46% |
| Nikkei 225 | 56,279.05 | 1,778.19 | -3.06% |
| NZX 50 Index | 13,620.21 | 102.76 | -0.75% |
| S&P 500 | 6,787.81 | 93.81 | -1.36% |
| S&P/ASX 200 | 9,077.30 | 90.80 | -0.99% |
| SSE Composite Index | 4,122.68 | 59.92 | -1.43% |